Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BPMC Blueprint Medicines	$129.46	$128.90	$73.04 ▼ $129.65	$8.36B	0.89	1.55 million shs	N/A
EBS Emergent Biosolutions	$7.79 -0.5%	$7.76	$4.02 ▼ $12.73	$417.74M	2.04	920,779 shs	917,664 shs
EVTCY Evotec	$3.69 +5.4%	$3.78	$14.22 ▼ $26.57	$1.22B	0.98	2,407 shs	50,143 shs
FOLD Amicus Therapeutics	$7.97 -0.5%	$7.04	$5.51 ▼ $12.65	$2.47B	0.55	3.59 million shs	4.99 million shs
PRGO Perrigo	$21.13 -1.1%	$24.67	$21.03 ▼ $30.93	$2.94B	0.48	1.42 million shs	1.92 million shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BPMC Blueprint Medicines	0.00%	0.00%	0.00%	+1.05%	+49.65%
EBS Emergent Biosolutions	-0.26%	-2.18%	-14.02%	+23.51%	+13.23%
EVTCY Evotec	+5.43%	+7.27%	-1.86%	-7.05%	+5.43%
FOLD Amicus Therapeutics	-0.50%	+0.38%	+7.56%	+39.09%	-28.84%
PRGO Perrigo	-1.08%	-4.41%	-8.31%	-19.76%	-24.60%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BPMC Blueprint Medicines	$129.46	$128.90	$73.04 ▼ $129.65	$8.36B	0.89	1.55 million shs	N/A
EBS Emergent Biosolutions	$7.79 -0.5%	$7.76	$4.02 ▼ $12.73	$417.74M	2.04	920,779 shs	917,664 shs
EVTCY Evotec	$3.69 +5.4%	$3.78	$14.22 ▼ $26.57	$1.22B	0.98	2,407 shs	50,143 shs
FOLD Amicus Therapeutics	$7.97 -0.5%	$7.04	$5.51 ▼ $12.65	$2.47B	0.55	3.59 million shs	4.99 million shs
PRGO Perrigo	$21.13 -1.1%	$24.67	$21.03 ▼ $30.93	$2.94B	0.48	1.42 million shs	1.92 million shs

A Guide To High-Short-Interest Stocks

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BPMC Blueprint Medicines	0.00%	0.00%	0.00%	+1.05%	+49.65%
EBS Emergent Biosolutions	-0.26%	-2.18%	-14.02%	+23.51%	+13.23%
EVTCY Evotec	+5.43%	+7.27%	-1.86%	-7.05%	+5.43%
FOLD Amicus Therapeutics	-0.50%	+0.38%	+7.56%	+39.09%	-28.84%
PRGO Perrigo	-1.08%	-4.41%	-8.31%	-19.76%	-24.60%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BPMC Blueprint Medicines	2.11	Hold	$130.00	0.42% Upside
EBS Emergent Biosolutions	3.00	Buy	$13.50	73.30% Upside
EVTCY Evotec	0.00	N/A	N/A	N/A
FOLD Amicus Therapeutics	2.78	Moderate Buy	$16.00	100.75% Upside
PRGO Perrigo	2.40	Hold	$33.00	56.18% Upside

Current Analyst Ratings Breakdown

Latest EBS, BPMC, FOLD, PRGO, and EVTCY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/3/2025	EBS Emergent Biosolutions	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$15.00
8/7/2025	PRGO Perrigo	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$42.00 ➝ $40.00
8/7/2025	PRGO Perrigo	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$38.00 ➝ $35.00
7/17/2025	FOLD Amicus Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Equal Weight ➝ Overweight

(Data available from 9/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BPMC Blueprint Medicines	$562.12M	14.87	N/A	N/A	$4.70 per share	27.54
EBS Emergent Biosolutions	$812.50M	0.51	$1.91 per share	4.08	$8.91 per share	0.87
EVTCY Evotec	$572.16M	2.13	$0.03 per share	105.53	$2.52 per share	1.46
FOLD Amicus Therapeutics	$571.16M	4.30	N/A	N/A	$0.65 per share	12.26
PRGO Perrigo	$4.37B	0.66	$5.00 per share	4.23	$31.66 per share	0.67

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BPMC Blueprint Medicines	-$67.09M	-$2.47	N/A	199.17	N/A	-27.70%	-64.60%	-17.22%	10/28/2025 (Estimated)
EBS Emergent Biosolutions	-$190.60M	$2.45	3.18	3.76	N/A	16.38%	24.63%	8.97%	11/5/2025 (Estimated)
EVTCY Evotec	$7.14M	$0.41	9.00	∞	N/A	20.85%	16.02%	7.81%	N/A
FOLD Amicus Therapeutics	-$56.11M	-$0.12	N/A	18.53	N/A	-6.67%	-5.07%	-1.23%	11/5/2025 (Estimated)
PRGO Perrigo	-$171.80M	-$0.58	N/A	6.91	N/A	-1.86%	9.09%	3.96%	11/5/2025 (Estimated)

Latest EBS, BPMC, FOLD, PRGO, and EVTCY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/6/2025	Q2 2025	EBS Emergent Biosolutions	-$0.26	$0.16	+$0.42	-$0.22	$148.55 million	$140.90 million
8/6/2025	Q2 2025	PRGO Perrigo	$0.59	$0.57	-$0.02	-$0.06	$1.08 billion	$1.06 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BPMC Blueprint Medicines	N/A	N/A	N/A	N/A	N/A
EBS Emergent Biosolutions	N/A	N/A	N/A	N/A	N/A
EVTCY Evotec	N/A	N/A	N/A	N/A	N/A
FOLD Amicus Therapeutics	N/A	N/A	N/A	N/A	N/A
PRGO Perrigo	$1.16	5.49%	N/A	N/A	23 Years

Latest EBS, BPMC, FOLD, PRGO, and EVTCY Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/30/2025	PRGO Perrigo	quarterly	$0.29	4.88%	8/29/2025	8/29/2025	9/16/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BPMC Blueprint Medicines	1.01	2.80	2.75
EBS Emergent Biosolutions	1.25	5.66	3.00
EVTCY Evotec	0.53	2.57	2.50
FOLD Amicus Therapeutics	1.92	3.21	2.29
PRGO Perrigo	0.81	2.32	1.24

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BPMC Blueprint Medicines	N/A
EBS Emergent Biosolutions	78.40%
EVTCY Evotec	N/A
FOLD Amicus Therapeutics	N/A
PRGO Perrigo	95.91%

Insider Ownership

Company	Insider Ownership
BPMC Blueprint Medicines	4.21%
EBS Emergent Biosolutions	1.20%
EVTCY Evotec	N/A
FOLD Amicus Therapeutics	2.20%
PRGO Perrigo	0.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BPMC Blueprint Medicines	640	64.58 million	61.86 million	Optionable
EBS Emergent Biosolutions	2,420	53.35 million	52.71 million	Optionable
EVTCY Evotec	4,200	330.22 million	N/A	Not Optionable
FOLD Amicus Therapeutics	480	308.24 million	301.46 million	Optionable
PRGO Perrigo	8,379	137.58 million	136.62 million	Optionable

EBS, BPMC, FOLD, PRGO, and EVTCY Headlines

Recent News About These Companies

13 Most Oversold Healthcare Stocks So Far in 2025

September 16 at 11:45 AM | insidermonkey.com

Perrigo Company plc (PRGO) Sells Dermacosmetics Unit in €327M Deal

September 16 at 11:45 AM | msn.com

AQR Capital Management LLC Has $4.99 Million Stake in Perrigo Company plc $PRGO

September 15 at 3:18 AM | marketbeat.com

Nicola Wealth Management LTD. Raises Stock Holdings in Perrigo Company plc $PRGO

September 14, 2025 | marketbeat.com

Perrigo Company plc $PRGO Shares Sold by Advisors Asset Management Inc.

September 14, 2025 | marketbeat.com

Royal Bank of Canada Has $11.62 Million Stock Holdings in Perrigo Company plc $PRGO

September 14, 2025 | marketbeat.com

Insider Buying: Perrigo (NYSE:PRGO) EVP Buys 1,255 Shares of Stock

September 12, 2025 | marketbeat.com

Analyst Report: Perrigo Company PLC

September 11, 2025 | finance.yahoo.com

Perrigo (NYSE:PRGO) EVP Abigail Lennox Acquires 1,255 Shares

September 11, 2025 | insidertrades.com

Dean Capital Management Purchases 36,162 Shares of Perrigo Company plc $PRGO

September 11, 2025 | marketbeat.com

Clearline Capital LP Trims Position in Perrigo Company plc $PRGO

September 10, 2025 | marketbeat.com

Millennium Management LLC Buys 2,013,856 Shares of Perrigo Company plc $PRGO

September 10, 2025 | marketbeat.com

Perrigo Company plc $PRGO Stock Position Lifted by Seven Six Capital Management LLC

September 9, 2025 | marketbeat.com

Wall Street Zen Upgrades Perrigo (NYSE:PRGO) to "Buy"

September 8, 2025 | marketbeat.com

Perrigo Company plc $PRGO Holdings Boosted by Ion Asset Management Ltd.

September 7, 2025 | marketbeat.com

Perrigo (NYSE:PRGO) Upgraded at Wall Street Zen

September 7, 2025 | americanbankingnews.com

Edmond DE Rothschild Holding S.A. Acquires 96,520 Shares of Perrigo Company plc $PRGO

September 6, 2025 | marketbeat.com

Perrigo Company plc $PRGO is Cutter Capital Management LP's 8th Largest Position

September 6, 2025 | marketbeat.com

Perrigo Company plc $PRGO Shares Acquired by BW Gestao de Investimentos Ltda.

September 5, 2025 | marketbeat.com

Vestal Point Capital LP Grows Stock Holdings in Perrigo Company plc $PRGO

September 4, 2025 | marketbeat.com

Aristotle Small/Mid Cap Equity WM Q2 2025 Commentary

September 3, 2025 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

EBS, BPMC, FOLD, PRGO, and EVTCY Company Descriptions

Blueprint Medicines NASDAQ:BPMC

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

Emergent Biosolutions NYSE:EBS

$7.79 -0.04 (-0.51%)

Closing price 09/17/2025 03:59 PM Eastern

Extended Trading

$7.80 +0.01 (+0.13%)

As of 04:00 AM Eastern

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.

Evotec OTCMKTS:EVTCY

$3.69 +0.19 (+5.43%)

As of 09/16/2025

Evotec SE engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. It operates through the following segments: EVT Execute and EVT Innovate. The EVT Execute segment provides stand-alone or integrated drug discovery solutions for collaborators targets and programmers on a typical fee-for-service basis or through a variety of commercial structures, which may include performance-based components, such as milestones and royalties. The EVT Innovate develops drug discovery projects, assets and platforms, both internally or through academic collaborations. The company was founded by Manfred Eigen, Karsten Henco, Ulrich Aldag, Freimut Leidenberger, Heinrich Maria Schulte, Rudolf Rigler, and Charles Weissmann on December 8, 1993 and is headquartered in Hamburg, Germany.

Amicus Therapeutics NASDAQ:FOLD

$7.97 -0.04 (-0.50%)

Closing price 09/17/2025 04:00 PM Eastern

Extended Trading

$8.41 +0.44 (+5.58%)

As of 06:31 AM Eastern

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.

Perrigo NYSE:PRGO

$21.13 -0.24 (-1.12%)

Closing price 09/17/2025 03:59 PM Eastern

Extended Trading

$21.33 +0.20 (+0.95%)

As of 05:14 AM Eastern

Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. It also offers healthy lifestyle products, such as smoking cessation, well-being, and weight management products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women's health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; rare diseases business; and other miscellaneous self-care products. The company sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, Compeed Stops, XLS, Arterin, Davitamon, Apiserum, Abtei, and Nicorette brands. It also offers contract manufacturing services. The company sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies. The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest EBS, BPMC, FOLD, PRGO, and EVTCY Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest EBS, BPMC, FOLD, PRGO, and EVTCY Earnings

Compare Dividends

Latest EBS, BPMC, FOLD, PRGO, and EVTCY Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

EBS, BPMC, FOLD, PRGO, and EVTCY Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

EBS, BPMC, FOLD, PRGO, and EVTCY Company Descriptions

Blueprint Medicines NASDAQ:BPMC

Emergent Biosolutions NYSE:EBS

Evotec OTCMKTS:EVTCY

Amicus Therapeutics NASDAQ:FOLD

Perrigo NYSE:PRGO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools